|
4 Companies |
|
10 Products |
|
10 Products |
|
12 Mechanisms of Action |
|
0 Trials |
|
12 News |
|
- Trial completion, Trial primary completion date: PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=20, Completed, Sponsor: dr. M.P. van den Tol MD PhD
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016
- Trial completion, Trial primary completion date: Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=754, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2016
- | Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Feb 22, 2014
P2, N=122, Completed, Sponsor: Genentech
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2016 No longer recruiting --> Completed
- Trial withdrawal, Gene therapy: Gene Therapy for Prostate Cancer That Returns After Radiation Therapy (clinicaltrials.gov) - Oct 22, 2013
P1, N=0, Withdrawn, Sponsor: Simon Hall
No longer recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change, Gene therapy: Gene Therapy for Prostate Cancer That Returns After Radiation Therapy (clinicaltrials.gov) - Oct 22, 2013
P1, N=0, Withdrawn, Sponsor: Simon Hall
Recruiting --> Withdrawn N=24 --> 0
- Enrollment open: PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=20, Recruiting, Sponsor: dr. M.P. van den Tol MD PhD
N=24 --> 0 Not yet recruiting --> Recruiting
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Trial termination: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Lack of Recruitment
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Enrollment change: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
Active, not recruiting --> Terminated; Lack of Recruitment N=450 --> 84
- Enrollment closed: Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy (clinicaltrials.gov) - Mar 10, 2013
P=N/A, N=750, Active, not recruiting, Sponsor: Seoul National University Hospital
N=450 --> 84 Recruiting --> Active, not recruiting
- ||||||| Litx (talaporfin) / Light Sciences Oncology
Trial completion: Phase 3 Trial of Litx (clinicaltrials.gov) - Nov 13, 2012
P3, N=483, Completed, Sponsor: Light Sciences Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Enrollment change: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 12, 2012
P2/3, N=129, Completed, Sponsor: Endo Pharmaceuticals
Active, not recruiting --> Completed N=105 --> 129
- ||||||| Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Trial completion: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 12, 2012
P2/3, N=129, Completed, Sponsor: Endo Pharmaceuticals
N=105 --> 129 Active, not recruiting --> Completed